A Phase 1b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Tolerability of Multiple Intravenous Doses of MEDI-545, a Fully Human Anti-Interferon-Alpha Monoclonal Antibody, in Patients With Systemic Lupus Erythematosus

Trial Profile

A Phase 1b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Tolerability of Multiple Intravenous Doses of MEDI-545, a Fully Human Anti-Interferon-Alpha Monoclonal Antibody, in Patients With Systemic Lupus Erythematosus

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Feb 2013

At a glance

  • Drugs Sifalimumab (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Adverse reactions; Biomarker; Pharmacogenomic
  • Most Recent Events

    • 28 May 2011 Results presented at the 12th Annual Congress of the European League Against Rheumatism.
    • 28 May 2011 Results presented at the 12th Annual Congress of the European League Against Rheumatism.
    • 06 Dec 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top